Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

John Ansell, MBA

John Ansell, MBA, Director, John Ansell ConsultancyDirector
John Ansell Consultancy
Member of the Healthcare Council

John Ansell, BSc, MA, has been a pharmaceutical industry consultant since 1990, based in Thame, near Oxford, UK. He was employed for 20 years in the industry by Organon, Schering AG, Fisons, Solvay and Glaxo. His experience there and subsequently as a consultant is chiefly in business development, licensing, and international marketing. Mr. Ansell is the author of some 40 articles and reports on pharmaceutical issues, many for Decision Resources Inc. (www.johnansell.com), and has acted as chairman at over 30 pharma conferences. He is a frequent speaker on various aspects of pharma deals, as well as on marketing and R & D strategy. He was founding director of IBC/Falconbury's Pharma Executive Mini-MBA course (2005-). In the US, Mr. Ansell has been a member of the Editorial Advisory Board of Pharmaceutical Executive (1990-2002), and Chairman of the Advisory Board of Decision Resources since its inception (2005-). (This is me - Update Profile)


Employment History
1990 - present Director
John Ansell Consultancy

GLG Study Groups with John Ansell, MBA(?)

GLG NewsSM Analyses by John Ansell, MBA(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Pfizer focuses down - but at the same time takes on more risk | 10-08-2008
Author: John Ansell, MBA, Director, John Ansell Consultancy

As the biggest pharmaceutical company, Pfizer's R & D needs to be more productive than any other company's if it is to survive and prosper. But Pfizer must have new products that are big if they are to make an impact on its bottom line. The conundrum is that disease is a diffuse market, with...

Chinese generics is nothing new | 05-21-2008
Analysis of: China Muscles In On The Generics Industry | www.pharmalot.com
Author: John Ansell, MBA, Director, John Ansell Consultancy

In 1976, sitting in my office in International Marketing at Fisons, Loughborough, UK, I used to watch the drums of bulk paracetamol arriving at the factory from China - easily recognizable from the Chinese script decorating them. I'm sure the UK wasn't the only country importing raw materials from China...

Abbott's Humira: a key step towards market leadership in psoriasis | 01-08-2008
Author: John Ansell, MBA, Director, John Ansell Consultancy

European approval for Humira in psoriasis is a key step towards leadership over the other monoclonal antibodies already approved - and because this is the most valuable category, leadership also of the total psoriasis market. In April 2007 Abbott submitted this indication for approval to...

Lundbeck and anticancer applications | 10-09-2007
Author: John Ansell, MBA, Director, John Ansell Consultancy

This move conforms with Lundbeck's strategy to concentrate on CNS areas and to bring in other parties to develop non-CNS applications.

GLG InstituteSM Seminars with John Ansell, MBA(?)

 
John Ansell, MBA has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with John Ansell, MBA









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-11-19T09:45:17.110